Skip to Content

Join the 'Glycopyrrolate' group to help and get support from people like you.

Glycopyrrolate News

Bevespi Aerosphere Approved by the FDA for Patients with COPD

Posted 30 Apr 2016 by Drugs.com

25 April 2016 – AstraZeneca today announced that the US Food and Drug Administration has approved Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Sean Bohen, Executive Vice-President, Global Medicines Development and Chief Medical Officer, said: “With the approval of Bevespi Aerosphere we are pleased to provide patients with the first LAMA/LABA in a pressurised metered-dose inhaler, delivered using our unique formulation technology. LAMA/LABAs are emerging as a preferred treatment option for many COPD patients. This class aims to provide maximum bronchodilation, which enables patients to breathe better and may help them be more active.” Bevespi Aerosphere is a twice-daily, ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Glycopyrrolate, Formoterol, Bevespi Aerosphere, Formoterol/glycopyrrolate

FDA Approves Seebri Neohaler (glycopyrrolate) for COPD

Posted 4 Nov 2015 by Drugs.com

EAST HANOVER, N.J., Oct. 29, 2015 Novartis announced today that the US Food and Drug Administration (FDA) has approved Seebri Neohaler (glycopyrrolate) inhalation powder 15.6 mcg as a stand-alone monotherapy for COPD. Novartis expects that Seebri Neohaler will be available in the first quarter of 2016. Seebri is delivered via the low resistance Neohaler inhaler, which makes it suitable for patients with different severities of airflow limitation. About Seebri Neohaler Seebri Neohaler, previously known as NVA237, is a twice-daily long-acting muscarinic antagonist (LAMA) for the long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. Glycopyrrolate (also known as glycopyrronium bromide) was exclusively licensed to Novartis in April 2005 by Vectura and its co-development partner Sosei. About Novartis Respiratory ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Glycopyrrolate, Seebri Neohaler

Common Class of Drugs May Be Linked to Pneumonia Risk

Posted 3 Mar 2015 by Drugs.com

TUESDAY, March 3, 2015 – Drugs used to treat a wide range of health problems may be associated with an increased risk of pneumonia, a new study suggests. Anticholinergic medications include those used for conditions such as allergies (for example, Benadryl), overactive bladder (including Ditropan), depression (for example, doxepin) and insomnia (Sominex, etc.). "Our study is the first to address whether oral anticholinergic medications affect the risk of pneumonia in older people," senior author Dr. Sascha Dublin, an associate investigator at the Seattle-based Group Health Research Institute, said in an institute news release. "This is important because so many older people use these medications, and pneumonia is such a common cause of illness and death in this age group," Dublin explained. Researchers looked at more than 1,000 patients with pneumonia, aged 65 to 94, and a group of ... Read more

Related support groups: Pneumonia, Bentyl, Hyoscyamine, Dicyclomine, Librax, Atropine, Donnatal, Scopolamine, Belladonna, Robinul, Levsin, Glycopyrrolate, Transderm-Scop, Antispasmodic, Symax Duotab, Scopace, Levsin SL, Methscopolamine, Hyosyne, Pro-Banthine

FDA Approves Cuvposa for Chronic Drooling in Children

Posted 2 Aug 2010 by Drugs.com

ROCKVILLE, Md., July 28, 2010--The U.S. Food and Drug Administration today approved Cuvposa (glycopyrrolate) Oral Solution to treat chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years. Drooling is normal in infants. But a significant proportion of the developmentally disabled population experiences drooling caused primarily by neuromuscular dysfunction that makes it hard to swallow. Cuvposa reduces drooling by lowering the volume of saliva produced. Glycopyrrolate was approved decades ago to treat peptic ulcers and reduce salivation in patients under anesthesia. Until now, glycopyrrolate has been used on an off-label basis to treat drooling in the developmentally disabled population, but in a different dosage form than the approved product. A drug is said to be used off-label when a physician prescribes its use in a different way than described in ... Read more

Related support groups: Glycopyrrolate

Ask a Question

Further Information

Related Condition Support Groups

Anesthesia, Excessive Salivation, Peptic Ulcer, Chronic Obstructive Pulmonary Disease, Maintenance

Related Drug Support Groups

Robinul, Seebri Neohaler, Robinul Forte, Glycate, Cuvposa

Glycopyrrolate Patient Information at Drugs.com